Asset profile
Leucettinib-21
Small molecule
Evidence outlook · lead readout
NCT06206824 · Healthy Volunteers, Down Syndrome, Alzheimer's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06206824: Several parts of this trial randomly assigned participants to Leucettinib-21 or a matching placebo, with everyone involved kept unaware of which treatment was given, which is a solid design for checking safety. But the trial was built to measure safety and drug-level readings rather than a disease outcome, and CT.gov has not yet posted results, so there is no read yet on how the drug performed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.